Search results
Found 10585 matches for
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
LungVax
LungVax: A Phase I Dose-escalation and Phase II Precision-Prevention trial of ChAdOx2-lungvax-NYESO vaccination for patients at risk of new or recurrent non-small cell lung cancer (NSCLC
Advancing CLL Management
This is a continuing professional development course promoting state of the art Chronic Lymphocytic Leukaemia diagnosis, management, and clinical research globally. This course is run in partnership with the International Workshop on Chronic Lymphocytic Leukemia (iwCLL).
Welcome
The Department of Oncology's mission is to improve cancer care through research and teaching. There is strong emphasis on translation, with established infrastructure to develop scientific insights toward clinical appreciation.